Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma

被引：1
|
作者：
Powles, Thomas [1 ]
Burgents, Joseph E. [2 ]
Xu, Lei [2 ]
Choueiri, Toni K. [3 ]
机构：
[1] Queen Mary Univ London, St Bartholomews Hosp, Barts Canc Inst, Expt Canc Med Ctr, London EC1M 6BQ, England
[2] Merck & Co Inc, Rahway, NJ USA
[3] Dana Farber Canc Inst, Boston, MA USA
来源：
LANCET ONCOLOGY | 2023年 / 24卷 / 01期
关键词：
D O I：
10.1016/S1470-2045(22)00740-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E1 / E2
页数：2
相关论文
共 50 条
  • [1] Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma
    Tarigopula, Vivek
    Nayak, Prasant
    Mandal, Swarnendu
    Das, Manoj Kumar
    Tripathy, Sambit
    LANCET ONCOLOGY, 2022, 23 (11): : 487 - 487
  • [2] The Continuing Question of Adjuvant Therapy in Clear Cell Renal Cell Carcinoma
    Berg, Stephanie. A. A.
    McGregor, Bradley. A. A.
    CANCERS, 2022, 14 (24)
  • [3] On KEYNOTE-564, evaluating pembrolizumab vs placebo as postnephrectomy adjuvant therapy for clear cell renal cell carcinoma
    Figlin, Robert A.
    ONCOLOGY-NEW YORK, 2021, 35 (07): : 381 - 381
  • [4] Adjuvant Pembrolizumab in Renal-Cell Carcinoma
    Chakiryan, Nicholas H.
    Strother, Marshall C.
    Choueiri, Toni K.
    Powles, Thomas
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (02): : 185 - 186
  • [5] Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy
    Mattila, Kalle E.
    Vainio, Paula
    Jaakkola, Panu M.
    CANCERS, 2022, 14 (01)
  • [6] Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab
    Serzan, Michael
    Atkins, Michael B.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (06) : 565 - 574
  • [7] Pembrolizumab: first adjuvant immunotherapy in renal cell carcinoma?
    Saleh, Khalil
    Kordahi, Manal
    Felefly, Tony
    Kourie, Hampig Raphael
    Khalife, Nadine
    FUTURE ONCOLOGY, 2022, 18 (05) : 519 - 522
  • [8] Adjuvant Pembrolizumab in Renal-Cell Carcinoma Reply
    Choueiri, Toni K.
    Powles, Thomas
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (02): : 186 - 186
  • [9] COMPARATIVE SURVIVAL OUTCOMES OF NON-CLEAR CELL RENAL CELL CARCINOMAS AND CLEAR CELL RENAL CELL CARCINOMAS WITH INDICATIONS FOR ADJUVANT PEMBROLIZUMAB
    Giacomo, Musso
    Margaret, Meagher
    Kit, Yuen
    Aaron, Ahdoot
    Dhruv, Puri
    Julian, Cortes
    Cesare, Saitta
    Dattatraya, Patil
    Hajime, Tanaka
    Melis, Guer
    Masaki, Kobayashi
    Shohei, Fukuda
    Francesco, Montorsi
    Alberto, Briganti
    Andrea, Salonia
    Umberto, Capitanio
    Alessandro, Larcher
    Yasuhisa, Fujii
    Viraj, Master
    Ithaar, Derweesh
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
  • [10] Adjuvant Therapy for Non-Clear Cell Renal Cell Carcinoma-The Ascent Continues
    Brown, Jacqueline T.
    JAMA NETWORK OPEN, 2024, 7 (08)
12345